Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Avon Technologies raises full-year guidance

(Sharecast News) - Avon Technologies raised its full-year guidance on Wednesday after reporting continued strong trading momentum in the second quarter, underpinned by robust demand across its defence and protective equipment businesses. The London-listed company said it now expected revenue growth in excess of 10% for the 2025 financial year, ahead of prior mid-single-digit expectations, and an adjusted operating margin above 12%, up from earlier guidance of around 11.5%.

It said the upgrade came after a solid first-half performance to 31 March, driven by the ramp-up of ACH Gen II helmet deliveries at Team Wendy to the US Department of Defense and strong sales of FM54 respirators and underwater rebreathers at Avon Protection.

The company also secured two new NATO-backed orders for FM50 and C50 respirators to support the Armed Forces of Ukraine, with deliveries set for 2025 and some extending into early in the 2026 financial year.

In addition, Avon Protection signed a new 12-year framework contract with two European navies for its MCM100 Multi-Role Rebreather systems.

While specific delivery volumes and timing were yet to be finalised, the agreement was expected to support long-term growth across accessories, training, and maintenance services.

Operating profit margins at Avon Protection were meanwhile benefiting from favourable product mix and ongoing efficiency improvements.

While costs related to the production ramp-up and factory closure at Team Wendy would weigh on first-half profitability, the group remains confident that margins will strengthen as the year progresses.

Management noted that scaling production for the US Department of Defense at Team Wendy continued to present both a risk and an opportunity, but efforts remained focused on mitigating challenges and unlocking further margin gains into the 2026 financial year.

All other guidance for 2025 remained unchanged.

"We are proud of the contribution that Avon continues to provide to the security of NATO nations," said chief executive officer Jos Sclater.

"The additional orders for provision of respiratory protection to Ukrainian war fighters and rebreathers for military divers allows both users to operate with confidence, knowing they are protected against increasingly prevalent threats in the harshest and most demanding environments."

Sclater said the company was continuing to deliver in accordance with its STAR strategy.

"Our growing order book, progress closing our California facility and the culture, capability change and pace we are seeing as we implement continuous improvement across the group all give us confidence for the medium term and beyond."

Avon said it would report its half-year results on 21 May.

At 0847 GMT, shares in Avon Technologies were up 6.4% at 1,457.59p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.